Viking Therapeutics is trading 4.04% down at $31.28; no new company-specific announcement was found for October 1.
- A recent $548 million stock and convertible-note offering has been a dilution concern, but does not establish a fresh catalyst for this session.
- Rising Treasury yields weighed on equities, with the 10-year yield reaching a 24-year high.
- Provided indices are down less than 0.5%, so broad-market pressure alone is not established as explaining the larger decline.